Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Int J Biol Macromol ; 138: 321-333, 2019 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-31295499

RESUMO

The aim of this study was to develop an effective wound dressing using a temperature-responsive hydroxybutyl chitosan (HBC) based hydrogel. The HBC - chitosan (CS) - dopamine (HCS-DOPA) composite hydrogels were prepared by the dopamine self-polymerization at different concentrations (0, 0.5, 1.0 and 2.0 mg/mL), termed as HCS, HCS-DOPA-0.5, HCS-DOPA-1 and HCS-DOPA-2, respectively. The gelling characteristic of HBC hydrogel was not influenced by composite CS and DOPA. The HCS-DOPA composite hydrogels were non-cytotoxic to mouse fibroblast cells (L929), and induced under 5.0% hemolysis rate. In vitro antibacterial studies, composite HCS-DOPA-2 hydrogels exhibited lasting inhibition to S. aureus >8 h. The whole blood test in vitro demonstrated that blood clotting time treated with HCS-DOPA-2 composite hydrogels was shortened to 95.6 s compared with that of HCS in vitro hemostasis. The results suggested that HCS-DOPA-2 composite hydrogels could be applied as a promising wound dressing for hemostasis in vitro.


Assuntos
Bivalves , Quitosana/química , Hemostasia/efeitos dos fármacos , Hidrogéis/química , Hidrogéis/farmacologia , Indóis/química , Polímeros/química , Temperatura , Animais , Antibacterianos/química , Antibacterianos/farmacologia , Materiais Biomiméticos/química , Materiais Biomiméticos/farmacologia , Coagulação Sanguínea/efeitos dos fármacos , Fenômenos Químicos , Escherichia coli/efeitos dos fármacos , Cinética , Staphylococcus aureus/efeitos dos fármacos
2.
Chin Med J (Engl) ; 120(23): 2081-5, 2007 Dec 05.
Artigo em Inglês | MEDLINE | ID: mdl-18167180

RESUMO

BACKGROUND: Gastric varices (GV) are life-threatening for patients with portal hypertension. Endoscopic injection with butyl cyanoacrylate (BC), the mainstay of the therapy for GV, has been reported to be effective for hemostasis of bleeding varices, but its efficacy in the obliteration of GV and impact on the survival of patients still needs clarification. Here we summarized our experience of 10 years' practice to evaluate the efficacy and safety of endoscopic therapy using BC for GV patients. METHODS: From January 1997 to April 2006, GV cases treated with endoscopic injection using BC were collected. The "sandwich method" and the "modified sandwich method" were used to inject BC intravascularly. Retrograde analysis was made on the data of treatment and follow-up. RESULTS: A total of 635 GV cases treated with endoscopic injection using BC were collected, most of them (90.2%) suffered from post-hepatitis cirrhosis. Emergency hemostasis was achieved in 139 out of 146 sessions (95.2%). Complications occurred in 32 cases (5.2%), including hemorrhage due to early expulsion of tissue glue (3.1%), septicemia (1%) and ectopic thrombosis (0.5%), such as spleen infarction. Endoscopic follow-up in 503 patients showed complete disappearance (76.9%), collapse (17.3%) or remnants (5.8%) of gastric varices. A total of 550 patients were followed up clinically for 3 to 115 months. Of these patients, 44 had recurrent bleeding (8.0%) and 44 died from hepatic failure, recurrent bleeding, hepatic carcinoma or other causes. The longest survival was 115 months, with a median survival of 25 months. Survival rates at 1, 2, 3, 4 and 5 year were 95%, 92%, 90%, 83% and 81%, respectively. CONCLUSIONS: Endoscopic sclerotherapy with BC is effective for the hemostasis of bleeding GV, as well as obliteration of GV which contributes to less rebleeding and better survival. The modified sandwich method may be useful to minimize ectopic embolism, which we speculated to result from excess iodized oil.


Assuntos
Embucrilato/uso terapêutico , Endoscopia Gastrointestinal/métodos , Varizes Esofágicas e Gástricas/terapia , Escleroterapia/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Varizes Esofágicas e Gástricas/mortalidade , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Escleroterapia/efeitos adversos , Adesivos Teciduais/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA